b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30753324</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>06</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1460-2156</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>142</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>03</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Brain : a journal of neurology</Title>\n                <ISOAbbreviation>Brain</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>733-743</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awz007</ELocationID>\n            <Abstract>\n                <AbstractText>Impulsive-compulsive behaviours like pathological gambling or hypersexuality are a frequent side effect of dopamine replacement therapy in patients with Parkinson\'s disease. Multiple imaging studies suggest a significant reduction of presynaptic dopamine transporters in the nucleus accumbens to be a predisposing factor, reflecting either a reduction of mesolimbic projections or, alternatively, a lower presynaptic dopamine transporter expression per se. Here, we aimed to test the hypothesis of fewer mesolimbic projections as a risk factor by using dopamine synthesis capacity as a proxy of dopaminergic terminal density. Furthermore, previous studies have demonstrated a reduction of fronto-striatal connectivity to be associated with increased risk of impulsive-compulsive behaviour in Parkinson\'s disease. Therefore, another aim of this study was to investigate the relationship between severity of impulsive-compulsive behaviour, dopamine synthesis capacity and fronto-striatal connectivity. Eighty participants underwent resting state functional MRI and anatomical T1-weighted images [mean age: 68 \xc2\xb1 9.9 years, 67% male (patients)]. In 59 participants, 18F-DOPA-PET was obtained and voxel-wise Patlak slopes indicating dopamine synthesis capacity were calculated. All participants completed the QUIP-RS questionnaire, a well validated test to quantify severity of impulsive-compulsive behaviour in Parkinson\'s disease. A voxel-wise correlation analysis between dopamine synthesis capacity and QUIP-RS score was calculated for striatal regions. To investigate the relationship between symptom severity and functional connectivity, voxel-wise correlations were performed. A negative correlation was found between dopamine synthesis capacity and QUIP-RS score in the nucleus accumbens (r = -0.57, P = 0.001), a region functionally connected to the rostral anterior cingulate cortex. The connectivity strength was modulated by QUIP-RS, i.e. patients with more severe impulsive-compulsive behaviours had a weaker functional connectivity between rostral anterior cingulate cortex and the nucleus accumbens. In addition, cortical thickness and severity of impulsive-compulsive behaviour were positively correlated in the subgenual rostral anterior cingulate cortex. We found three factors to be associated with severity of impulsive-compulsive behaviour: (i) decreased dopamine synthesis capacity in the nucleus accumbens; (ii) decreased functional connectivity of the rostral anterior cingulate cortex with the nucleus accumbens; and (iii) increased cortical thickness of the subgenual rostral anterior cingulate cortex. Rather than a downregulation of dopamine transporters, a reduction of mesolimbic dopaminergic projections in conjunction with a dysfunctional rostral anterior cingulate cortex-a region known to play a key role in impulse control-could be the most crucial neurobiological risk factor for the development of impulsive-compulsive behaviours in patients with Parkinson\'s disease under dopamine replacement therapy.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hammes</LastName>\n                    <ForeName>Jochen</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Theis</LastName>\n                    <ForeName>Hendrik</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Giehl</LastName>\n                    <ForeName>Kathrin</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hoenig</LastName>\n                    <ForeName>Merle C</ForeName>\n                    <Initials>MC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Greuel</LastName>\n                    <ForeName>Andrea</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, University Hospital of Marburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tittgemeyer</LastName>\n                    <ForeName>Marc</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Max Planck Institute for Metabolism Research, Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Cologne Cluster of Excellence in Cellular Stress and Aging-Associated Disease (CECAD), University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Timmermann</LastName>\n                    <ForeName>Lars</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, University Hospital of Marburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fink</LastName>\n                    <ForeName>Gereon R</ForeName>\n                    <Initials>GR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center J\xc3\xbclich, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Drzezga</LastName>\n                    <ForeName>Alexander</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>German Center for Neurodegenerative Diseases (DZNE), Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Eggers</LastName>\n                    <ForeName>Carsten</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, University Hospital of Marburg, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>van Eimeren</LastName>\n                    <ForeName>Thilo</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Multimodal Neuroimaging Group, Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center J\xc3\xbclich, Germany.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>German Center for Neurodegenerative Diseases (DZNE), Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Brain</MedlineTA>\n            <NlmUniqueID>0372537</NlmUniqueID>\n            <ISSNLinking>0006-8950</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C493214">SLC6A3 protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>VTD58H1Z2X</RegistryNumber>\n                <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>AIM</CitationSubset>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>Brain. 2019 Mar 1;142(3):496-498</RefSource>\n                <PMID Version="1">30810212</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName>\n                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName>\n                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009714" MajorTopicYN="N">Nucleus Accumbens</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Parkinson\xe2\x80\x99s disease</Keyword>\n            <Keyword MajorTopicYN="Y">imaging</Keyword>\n            <Keyword MajorTopicYN="Y">impulsivity and inhibition disorders</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>08</Month>\n                <Day>01</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>23</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>11</Month>\n                <Day>28</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>2</Month>\n                <Day>13</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30753324</ArticleId>\n            <ArticleId IdType="pii">5310124</ArticleId>\n            <ArticleId IdType="doi">10.1093/brain/awz007</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'